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Abstract  
Histone deacetylases (HDACs)
1
 play important roles in the epigenetic regulation of gene expression 
in cells and are emerging therapeutic targets for treating a wide range of diseases. HDAC inhibitors 
(HDACi)
2
 that act on multiple HDAC enzymes have been used clinically to treat a number of solid 
and hematological malignancies. HDACi are currently being studied also for their efficacy in non-
malignant diseases, including pathologic bone loss, but this has necessitated a better understanding 
of the roles of individual HDAC enzymes, particularly the eleven zinc-containing isozymes. 
Selective isozyme-specific inhibitors currently being developed against class I HDAC (1, 2, 3 and 
8) and class II HDAC (4, 5, 6, 7, 9 and 10) will be valuable tools for elucidating the roles played by 
individual HDACs in different physiological and pathological settings. Isozyme-specific HDACi 
promise to have greater efficacy and reduced side effects, as required for treating chronic disease 
over extended periods of time. This article reviews the current understanding of roles for individual 
HDAC isozymes and effects of HDACi on bone cells, (osteoblasts, osteoclasts and osteocytes), in 
relation to bone remodelling in conditions characterised by pathological bone loss, including 
periodontitis, rheumatoid arthritis and myeloma bone disease.  
 
Key words: Histone deacetylases (HDAC), osteoclasts, osteoblasts, periodontitis, rheumatoid 
arthritis, myeloma bone disease.  
 
 
 
 
                                                          
1 Histone deacetylases (HDACs) 
2 HDAC inhibitors (HDACi) 
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1. Introduction 
Epigenetic regulation of gene expression in cells is an important process enabled, in part, by 
a mechanism involving histone deacetylases (HDAC). Modulation of these enzymes using HDAC 
inhibitors (HDACi) is emerging as a promising treatment not only for cancer [1-3] but also for 
neurodegenerative diseases, asthma, rheumatoid arthritis, viral infections and malaria [4-11]. A 
number of HDACi have progressed to the clinic, or are in clinical trials, for treating solid and 
haematological tumours [1-3]. These include vorinostat (SAHA) and romidepsin (Istodax), both 
FDA approved for cutaneous T-Cell lymphoma (CTCL); panobinostat (LBH589, phase III, CTCL 
and approved for the treatment of multiple myeloma in 2015); quisinostat (JNJ-26481585, phase II, 
CTCL), belinostat (PXD101, phase II, ovarian, Tcell lymphoma), entinostat (MS-275, phase II, 
melanoma, Hodgkin’s lymphoma, lung, breast), resminostat (4SC-201, Hodgkin’s lymphoma, 
hepatocellular carcinoma), mocetinostat (MGCD0103, phase II, B cell cancers, lymphomas), 
abexinostat (phase II, FL), givinostat (ITF2357, phase II, leukemias, myelomas), chidamide (solid 
tumours) and practinostat (prostate cancer).  
The vast majority of HDACi are ‘pan’ inhibitors, targeting multiple HDACs in both class I 
and II. In most cases, the exact HDAC inhibition profile of these broad-spectrum drugs is unknown 
or varies with cell type and context, which can lead to possible side effects. Furthermore, there is 
likely to be some redundancy between HDAC enzymes that could complicate the development of 
inhibitors with target-specific effects or the interpretation of their in vivo properties. Research in 
this area is increasingly focussing on development and application of class- or isozyme-specific 
HDACi in order to improve efficacy and reduce potential side effects. More selective HDACi can 
be valuable tools for understanding the cellular distribution and actions of individual HDAC 
isozymes in both physiological and pathological settings.  
Broad acting HDACi, such as trichostatin A (TSA), vorinostat (suberanilohydroxamic acid) 
and romidepsin (FK228, Istodax), have been used clinically in the areas of psychiatry and cancer. 
More recently, the effects of several broad acting HDACi on bone metabolism have been examined 
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in a number of in vitro and in vivo studies with effects on osteoclasts and osteoblasts identified [12-
20]. HDACi have also been shown to suppress inflammation and disease progression in a number 
of animal models of rheumatoid arthritis (RA) [7, 21-23]. Despite this, only one HDACi, 
Givinostat, has so far progressed to clinical trials for the treatment of juvenile arthritis [24]. 
Importantly, HDACi can be used at lower, non-cytotoxic, doses to treat non-malignant disease than 
is required to treat malignancy [25]. However, they need to be used long-term for the treatment of 
chronic inflammatory diseases and residual or cumulative toxicity may have contributed to their 
lack of progression to the clinic. The 18 HDAC enzymes are widely expressed in tissues throughout 
the body and deacetylate both histone and non-histone proteins, making it challenging to determine 
the precise mechanism of action of different HDACi. Despite the ubiquitous nature of class I 
HDACs, differences in expression of these enzymes have been observed in a number of 
malignancies and also in rheumatoid arthritis (RA) [26-29]. This review focuses on HDACs and 
HDACi in both physiological and pathological bone turnover. Specifically, it will focus on the 
current understanding of the roles played by HDACs in osteoclast, osteoblast and osteocyte 
development and function. In addition, we evaluate the limited studies to date that show effects of 
some HDACi (broad acting, class-specific and isozyme-specific) in vitro and in vivo in models of 
pathological bone loss, including rheumatoid arthritis, periodontitis and myeloma bone disease.  
1.1 Histone deacetylase enzymes 
There are 18 human HDACs grouped into 4 classes. Eleven contain a catalytic zinc (HDACs 
1 to 11) while seven are NAD
+
-dependent enzymes (SIRT 1 to 7). Class I is made up of HDACs 1, 
2, 3 and 8 that are primarily restricted to the nucleus. HDACs 4, 5, 7 and 9 belong to class IIa and 
HDACs 6 and 10 belong to class IIb (see Table 1). Class II HDACs are able to shuttle between the 
nucleus and cytoplasm [30]. Class III HDACs, also called sirtuins (SIRT 1-7), are found in the 
cytoplasm and require a co-factor NAD
+
 for activation. These enzymes do not have a catalytic zinc 
and act by a different mechanism to class I and II HDACs.  HDAC 11 is the only member of Class 
IV HDACs and is similar to classes I and II HDACs in both sequence and presence of a catalytic 
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zinc ion [4, 30, 31]. Given Class III HDACs function by a very different mechanism to class I and II 
they will not be considered in this review. 
 
1.2 Histone Deacetylase Inhibitors 
HDACi have a metal binding moiety that interacts with the zinc dependent catalytic domain of class 
I and II HDACs. Inhibitors also have a capping group that interacts with residues found at the 
entrance to the active site and a linking structure that helps to align the binding moiety and capping 
group within the active site [32]. There is a high structural similarity between the HDAC enzymes 
and hence a large number of the HDACi researched to date are pan inhibitors. Class- or isozyme-
specific HDACi are designed in the same manner as pan inhibitor but this requires accurate 
knowledge of the protein structures of the individual isozymes to enable determination of subtle 
differences that may exist within the active sites [33]. It is also important to consider how these 
enzymes function with other proteins within cells. For instance, HDAC 1 and 2 function within 
multi-protein complexes including Sin3A, NuRD and CoREST [34] whilst HDAC 3 functions 
within SMRT and N-CoR complexes [35]. Class IIa HDACs have a number of levels of regulation 
(transcriptional control, translational control including micro RNAs, proteolytic control and 
phosphorylation) and they also function in multi-protein complexes (as reviewed in [36]). These 
different levels of control and the protein complexes can complicate the trafficking and availability 
of specific HDAC targets but doesn’t usually result in any modification to the catalytic sites of the 
enzymes. The high structural similarity and sequence conservation between HDAC isozymes in the 
same class has also limited the design and development of isozyme-specific inhibitors.  Possible 
mechanisms that have been used or proposed to contribute in the development of isozyme-specific 
inhibitors include modifications to the binding moiety, capping region and linkers [32]. 
Combinations of these modifications are useful in developing class- or isozyme-specific inhibitors 
[32].  
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2. Osteoclasts, HDACs and HDACi 
Osteoclasts are large multinucleated cells derived from the haematopoietic lineage that 
function to resorb bone tissue during bone maintenance, repair and remodelling. In bone loss 
diseases, including osteoporosis, RA, periodontitis and multiple myeloma, increased numbers of 
osteoclasts and high levels of Receptor Activator of Nuclear Factor Kappa B ligand (RANKL) have 
been reported [37-42]. Over the past decade, numerous studies have shown that RANKL, produced 
by cytokine-activated lymphocytes, fibroblasts and plasma cells, drives excessive osteoclast-
mediated bone resorption in RA, periodontitis and multiple myeloma, respectively [37, 38, 40, 43]. 
Initial studies in 2003 demonstrated that broad spectrum HDACi (TSA and sodium butyrate) could 
inhibit osteoclast formation and activity using rat bone marrow cells with concentrations of 5 nM 
TSA or 0.5 mM NaB shown to inhibit TRAP cell formation [20]. Since then, a number of studies 
have reported on suppression of osteoclastogenesis in murine cell lines and primary human 
osteoclasts with broad acting HDACi including TSA, FR901228 and 1179.4b [15, 19, 20, 44, 45]. 
Osteoclastogenesis suppression is thought to occur through targeting of the osteoclast intercellular 
signalling factors following RANK/RANKL interaction, such as early activation of tumour necrosis 
factor (TNF) receptor associated factor-6 TRAF-6 (1179.4b) [19] and the transcription factor c-fos 
(TSA) [13]. HDACi (FR901228 and 1179.4b) have also been shown to induce proteosomal 
degradation of the NF-B-IB complex via ubiquination pathways and to directly act on key 
osteoclast transcription factors NF-B and nuclear factor of activated T cells (NFATc1) [15, 19].  
Other studies have demonstrated that HDACi (FR901228) can induce expression of osteoclast 
inhibitory factors such as interferon β (IFN-β) [15]. Although these broad acting HDACi have 
promising effects in suppressing osteoclast differentiation and activity, the significance of 
individual HDACs in this process remains to be fully elucidated and is the subject of considerable 
investigation. To this end, both class specific HDACi and/or knockdown of the specific isozymes 
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with small interfering RNA (siRNA) or short hairpin RNA (shRNA) have enabled roles of 
individual HDACs in osteoclast differentiation to be investigated.  
2.1 Role of Class I HDACs in osteoclast differentiation and bone resorption. 
HDAC 1 and 2, both members of class I HDACs, are structurally similar enzymes that 
function together in a protein complex [46]. For this reason, it is thought that there is redundancy 
between the two enzymes [34]. We and others have shown that the HDAC1-selective inhibitor MS-
275 (IC50 181 nM HDAC 1, 1160 nM HDAC 2; Table 2) suppresses osteoclast formation in a 
concentration dependent manner [19]. In vitro, 100 nM MS-275 significantly suppressed both the 
formation of tartrate resistant acid phosphatase (TRAP) positive human osteoclasts and their 
subsequent resorptive ability [19]. Using mouse bone marrow-derived macrophages (BMMs), MS-
275 (20-100 nM) was shown by others to suppress RANKL-induced osteoclast formation and 
activity by inhibiting expression of c-fos and NFATc1 in a concentration-dependent manner. 
Furthermore, an equipotent inhibitor in vitro of both enzymes HDAC 1 and 2, NW-21 (IC50 21 nM 
HDAC1, 42 nM HDAC2; Table 2) developed at the University of Queensland, has been found to 
suppress human osteoclast formation and activity in a concentration-dependent manner (0.16-100 
nM) as well as reduce osteoclast formation via suppression of TRAF-6 and NFATc1 [19]. The 
higher potency of NW-21 (IC50 4 nM) [19] over MS-275 (IC50 54 nM) [19] in cells supports a role 
for both HDAC 1 and 2 in osteoclast differentiation and activity.  
In addition to HDAC 1 and 2, HDAC 3 and 8 are also members of class I HDACs. To date, 
only one study has examined the role of HDAC 3 in osteoclasts using shRNA in murine BMMs 
[47]. HDAC 3 shRNA resulted in down regulation of NFATc1, cathepsin K and DC-STAMP [47].  
Similarly, HDAC 8 mRNA expression was shown to be significantly higher during the later stages 
of human osteoclast differentiation in vitro [19]. To date, no studies have reported the effects of 
selective HDAC 8 inhibitors on osteoclast differentiation and function.  
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A recent study showed that MPT0G009, a non-specific HDACi that targets HDACs of both 
class I (HDAC 1, 2, 3, 8) and class IIb (HDAC 6) (Table 1), suppressed the formation of TRAP+ 
multinucleated cells from RAW264.7 mouse macrophages at concentrations as low as 5 nM [21]. 
This compound was compared to vorinostat, a similarly broad acting but less potent HDACi, which 
had no effect on osteoclast formation at 50 nM. In this study, MPT0G009 suppressed osteoclast 
differentiation by targeting key osteoclast transcription factors NF-kB and NFATc1. These effects 
suggest that it may be important to target multiple HDACs to effectively suppress osteoclasts. 
Collectively, these studies have begun to elucidate the roles of class I HDACs in osteoclast 
formation and activity. Notably, suppression of key osteoclast transcription factors NF-B and 
NFATc1 appear to be common mechanisms of action for HDACi studied to date. NFATc1 is a key 
transcription factor required for osteoclast formation and induces expression of osteoclast genes 
during late stages of osteoclast formation, including TRAP, calcitonin receptor (CTR), cathepsin K, 
tartrate resistant acid phosphatase (TRAP) and β3 integrin [48-50]. Similarly, NF-B is an 
important transcription factor involved in osteoclast formation, activation and survival [51].  
2.2 Role of Class II HDACs in osteoclast differentiation and bone resorption. 
Class II HDACs have the ability to shuttle between the cell nucleus and the cytoplasm. 
HDAC 5 is a class IIa HDAC that has been shown to induce NFATc1 deacetylation, leading to 
down-regulation of its transcriptional activity. In BMM, overexpression of HDAC 5 impairs 
RANKL-induced osteoclast differentiation [52]. Recent studies have shown that in human 
osteoclasts, HDAC 5 mRNA is significantly increased during the later stages of differentiation in 
vitro [19]. To date, no studies have reported on inhibitors targeting HDAC 5 and their effects on 
osteoclasts. 
HDAC 6 is a mainly cytoplasmic protein of class IIb HDACs that act on both histones and 
the cytoplasmic protein tubulin [53]. It also plays an important role in the process of autophagy by 
controlling fusion of autophagosomes to lysosomes [54]. A novel HDACi, 2664.12, that targets 
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class II HDACs has been shown to have selective affinity for HDAC 6 (IC50 29 nM HDAC 6) 
(compound 17a in [55]) was able to suppress the activity of human osteoclasts in vitro at 20-100 
nM [19]. The broad spectrum HDACi, MPT0G009, that inhibits multiple HDACs including HDAC 
6 (IC50 8 nM, Table 2), was shown to suppress osteoclast differentiation and activity in human and 
murine RAW264.7 cells, respectively [21]. Recent studies support the idea that inhibition of both 
class I (HDAC 1) and II (HDAC 6) HDACs may be necessary to suppress osteoclast differentiation 
and activity. For example, using human osteoclasts, differentiated from PBMCs, the combination of 
MS-275 (targets HDAC 1) and 2664.12 (targets HDAC 6) suppressed multinucleated TRAP cell 
formation and activity far more effectively (IC50 0.4 nM) than when used on their own [19]. 
Furthermore, the effects observed with the combination of both compounds were similar to those 
observed for a broader spectrum HDACi (1179.4b) that targets both class I and II HDACs [19]. 
HDAC 7, a class IIa HDAC, may also have a role in regulating osteoclast differentiation and 
activity. Overexpression of HDAC 7 in mouse BMMs was shown to inhibit the fusion of osteoclast 
precursors through suppression of Mitf transcriptional activity [47]. In a subsequent study, 
overexpression of HDAC 7 in mouse bone marrow cells inhibited both the number and size of 
TRAP positive multinucleated cells formed. Notably, knockdown of HDAC 7 (HDAC 7 flox/flox; 
Ly-cre) has been found to enhance osteoclast differentiation. In this study, HDAC 7 was found to 
attenuate NFATc1 suppression of β-catenin in the presence of RANKL [56]. These studies suggest 
that inhibitors targeting HDAC 7 alone may not be sufficient to suppress the enhanced osteoclast 
differentiation and activation observed in a number of bone loss diseases.  
HDAC 9 expression has been recently shown to be down-regulated following RANKL 
stimulation of mouse bone marrow cells. Moreover, osteoclast differentiation and bone resorption 
was significantly elevated in HDAC 9 KO mice, suggesting that inhibitors targeting HDAC 9 could 
potentially have negative effects on bone [57]. 
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To date there have been no reports on elucidating the roles of class II HDACs 4 or 10 in 
osteoclast differentiation. The majority of studies on osteoclasts have focussed on inhibitors that 
have some affinity for class I HDACs, most likely due to the lack of class II specific inhibitors. 
Select studies demonstrating effects of targeting select class II HDACs and the use overexpression 
studies does suggest they may be appropriate targets to suppress osteoclasts that require further 
investigation as more selective acting HDACi are developed. 
  
3. Osteoblasts, HDACs and HDACi 
Osteoblasts are cells derived from the mesenchyme cell lineage that form bone. These cells 
are a major source of RANKL, which binds to its receptor RANK on pre-osteoclasts, resulting in 
the formation of active multinucleated osteoclasts [58]. The coupling of osteoblasts and osteoclasts 
is vital for homeostatic bone remodelling and maintenance of bone mass [59].  In pathological bone 
loss, there is an uncoupling of bone formation and resorptive processes leading to excessive bone 
loss. While diseases such as osteoporosis, periodontitis, RA and multiple myeloma are characterised 
by enhanced osteoclast resorption there are also reports of reduced osteoblast bone formation [60-
62]. For this reason, osteoblasts have been targeted with anabolic agents including parathyroid 
hormone (PTH), bone morphogenetic proteins (BMPs), as well as sclerostin neutralising antibody, 
in order to stimulate bone formation [63].  
As highlighted in other review articles [64, 65], a number of studies have suggested a role 
for specific HDACs in regulating osteoblast differentiation and maturation. Several studies have 
shown that broad acting HDACi (Valproate, TSA, butyrate) can increase osteoblast proliferation 
and the transcriptional activity of Runx2, leading to increased alkaline phosphatase (ALP) 
expression and mineralization in vitro [17, 66, 67] (Table 2).  
3.1 Role of Class I HDACs in osteoblast differentiation and bone formation. 
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Butyrate, a broad acting but very weak HDACi, has been shown to accelerate osteogenesis 
[14]. HDAC 1 is thought to be a key target of butyrate and has been reported to play a role in 
osteoblast differentiation, with its activity declining during osteoblast maturation [14]. This notion 
is supported by studies showing that siRNA-mediated suppression of HDAC 1 can stimulate 
osteoblast maturation [14]. Treatment of MC3T3-E1 cells, primary osteoblasts and mouse calvarial 
cultures with HDAC1 inhibitor MS-275 (500 nM for 3 days) stimulated cell proliferation and 
promoted ALP production [17], suggesting that class I HDAC 1 functions to suppress osteoblast 
differentiation.   
HDAC 3 (Class I) has been shown to interact with Runx2, repressing the activation of the 
osteocalcin promoter. HDACi (TSA) and shRNA to HDAC3 were able to reverse this repression 
[16]. In these studies, suppression of HDAC 3 in MC3T3 pre-osteoblasts accelerated expression of 
Runx2 target genes, osteocalcin, osteopontin, and bone sialoprotein. Mineralisation also occurred 
earlier in these cells [16]. In subsequent studies, conditional knockout of HDAC 3 in mature 
osteoblasts resulted in a decrease in postnatal cortical and trabecular bone mass [68]. Osteoblasts 
from these mice demonstrated reduced functional capabilities both in vitro and in vivo. These 
contrasting findings demonstrate the complex nature of HDACs and their role in bone cell 
development and function. Effects of suppressing HDAC 3 may be dependent upon the stage of 
osteoblast development and hence further studies are necessary to investigate the potential of 
selective acting HDAC 3 inhibitor. Roles for other class I HDACs, including HDAC 2 and 8, in 
osteoblast differentiation have not yet been reported.   
Effects of a selective class I HDACi, largazole, on osteogenic capacity were assessed using 
murine pluripotent mesenchymal precursor C2C12 cells. Treatment with largazole was shown to 
decrease total HDAC activity and, at a concentration of 50 nM, stimulated increased expression of 
ALP, osteopontin and Runx2, along with inducing expression of BMP-2, 4, 6, 7, and 9 [69].   
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Collectively, these studies highlight the importance of inhibiting class I HDACs, particularly 
HDAC 1, in enhancing osteoblast differentiation and hence mineralization. Further studies to assess 
effects of HDAC 1 selective inhibitors versus other HDACi on osteoblasts would be of considerable 
interest.  
3.2 Role of Class II HDACs in osteoblast differentiation and bone formation. 
Several studies have investigated the role of class II HDACs in osteoblast differentiation. 
For example, HDAC 4 is suppressed by miR-29b, resulting in induction of osteogenesis [70]. In 
contrast, studies utilizing HDAC 4 KO mice demonstrated that HDAC 4 regulates chondrocyte 
hypertrophy and endochondral bone formation. This was shown to be via inhibition of Runx2 
activity. The effect of inhibiting HDAC 4 could be dependent upon the stage of development [71]. 
 Interestingly, a recent meta-analysis of five genome-wide association studies of femoral 
neck and lumbar spine BMD demonstrated that HDAC 5 is a bone mineral density locus [72]. This 
is consistent with the observation that a novel miRNA targeting HDAC 5 promotes osteoblast 
differentiation in primary mouse osteoblasts [73] and is further highlighted by the observation that 
adolescents suffering from primary osteoporosis exhibit mutations resulting in a loss of miR-2861 
[73]. Notably, bone samples from these patients had increased HDAC 5 levels and correspondingly 
low Runx2 levels. These studies are consistent with HDAC 5 suppressing bone formation and 
selective HDAC 5 inhibitors elevating bone formation, although this has yet to be investigated.  In 
contrast, a recent study revealed that HDAC 5 global knockout mice have reduced numbers of 
osteoblasts and hence low bone density [74].  This study focused on the fact that HDAC 5 knockout 
increases SOST expression by osteocytes. Studies using HDAC 5 selective inhibitors on the 
different stages of osteoblast development and subsequent bone formation are very much needed. It 
is also important that studies utilize in vivo models to determine effects of these selective acting 
HDACi on the osteoclasts and osteocytes as well. 
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HDAC 6 is a class IIb HDAC that is reported to bind to Runx2 in differentiating osteoblasts 
[75]. HDAC 7 has been shown to suppress Runx2 activity during osteoblast maturation with RNAi 
suppression of HDAC 7 increasing osteoblast differentiation [12].  
To date, no studies have reported HDAC 4, 5, 6, or 7 selective inhibitors to investigate the 
roles of these enzymes in osteoblast differentiation and mineralization. It is likely that these 
inhibitors will have potential to stimulate osteoblast bone formation given the interactions of HDAC 
5, 6 and 7 with transcription factor Runx2. Studies to date, however, have suggested conflicting 
results in regard to the roles of select HDACs in bone formation, for instance HDAC 4 and 5. Hence 
further studies are necessary to unravel the roles of these enzymes in the different stages of 
osteoblast development and function.  
 
3.3 General effects of HDACi on bone formation 
NFATc1 expression is suppressed in osteoclasts treated with HDACi, 1179.4b and 
FR901228 [15, 19]. Activation of NFATc1 has been previously shown to significantly inhibit 
osteoblast differentiation and activity via repression of osteocalcin. [76]. Thus HDACi that suppress 
NFATc1 may be able to both inhibit bone resorption and enhance osteoblast bone formation.  
In contrast, a recent study suggests that the broad acting HDACi vorinostat can lead to bone 
loss, however doses were very high (100 mg/kg), equivalent to those used in pre-clinical models to 
treat malignancies. Using an in vivo model, it was demonstrated that vorinostat resulted in bone loss 
and reduced osteoblast numbers in mice [77]. Despite a negative effect on the immature osteoblasts, 
an increase in local bone formation was observed, with mature osteoblasts possibly being resistant 
to HDACi-induced apoptosis [77]. Selective targeting and lower doses (10-100x lower) of HDACi 
have been shown to be better tolerated in animal models and have different effects on bone cells 
without the induction of apoptosis. This is supported by a recent in vitro study demonstrating that 
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higher doses of vorinostat induced apoptosis of mesenchymal stem cells, but was not observed 
when lower doses were used [78].  
While our current understanding of the roles of HDAC 1 and 3, along with a number of class 
II HDACs, in osteoblast differentiation remains limited, it is clear that it is essential to determine 
whether targeting one HDAC alone is more effective or whether a combination of HDACs need to 
be targeted to affect osteoblast proliferation and differentiation. Of particular interest are the effects 
that isozyme-specific HDACi have on various stages of osteoblast differentiation and function.  
 
4. HDACs and inhibitors: Osteocytes 
Osteocytes are the predominant cell type residing in bone, comprising up to 90-95% of all 
bone cells. The importance of these cells and the roles they play in all aspects of bone remodelling 
is becoming increasingly evident [59, 79]. The important anabolic effects of these cells is 
highlighted by their role in osteoid mineralisation, with the rate of mineralisation thought to be 
controlled by these cells [80]. Osteocytes have also been recently identified as a major source of the 
osteoclast differentiation factor, RANKL [81, 82].  In addition, osteocytes which have undergone 
apoptosis have been shown to be the major stimulator of osteoclast resorption, with apoptotic 
bodies released from the cells expressing RANKL [83]. Sclerostin (SOST), which is expressed by 
osteocytes, also plays an important role in stimulating osteoclasts with studies demonstrating that 
osteocyte cell line MLO-Y4 cells treated with sclerostin produce increased levels of RANKL which 
can stimulate osteoclast resorption in co-cultures. [81]. To date, only two studies have attempted to 
elucidate the roles of class I and II HDACs in SOST regulation [84] [74]. HDAC 1, 2 and 5 mRNA 
were found to be strongly expressed in an osteoblast cell line, UMR106, used to assess SOST gene 
regulation by PTH [84]. Combinations of siRNA to HDAC 1, 2 and 3 resulted in 79% inhibition of 
SOST expression [84]. In a recent study, shRNA to class IIa HDAC 5 was shown to increase SOST 
expression in cell line Ocy454 osteocytes. Osteocyte marker DMP-1 was also increased with 
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HDAC 5 knockdown but there was no effect on expression of PHEX. shRNA to HDAC 4 or 7 in 
these cells did not increase SOST expression [74]. In subsequent studies, HDAC 5 global knock out 
mice were shown to have higher numbers of sclerostin secreting osteocytes particularly the peri-
endosteal osteocytes. In these mice, histomorphometric analysis also revealed a defect in bone 
formation and reduced osteoblast numbers but no changes in osteoclast parameters [74]. These 
results would suggest that HDACi targeting HDAC 5 may in fact have negative effects in regards to 
bone formation, by increasing osteocyte SOST expression. It is important to note though that 
HDAC 5 was absent in all cells not just osteocytes in the knockout mouse studies.  Targeting class I 
HDAC (1,2,3) may however have opposite effects and hence further studies are necessary using 
selective acting HDACi to elucidate their potential.   
 
5. Cross-talk between bone cells 
The majority of in vitro studies conducted using HDACi have focussed on individual bone cells e.g. 
osteoclasts, osteoblasts or osteocytes demonstrating direct effects on the cell differentiation or 
activity. In osteoclasts, HDACi have been shown to suppress key transcription factors such as 
NFATc1 and NF-B [15, 20, 85]. HDACi (FR901228) was shown to prevent the nuclear 
translocation of NFATc1 via induction of osteoclast inhibitory factor IFN-β [15].  Other studies 
have only assessed the expression of gene and protein NFATc1 in response to HDACi treatment 
and hence it is not clear exactly how HDACi alter acetylation levels leading to NFATc1 
suppression. In regards to NF-B, studies have revealed that select HDACi have the ability to 
suppress NF-B p65 nuclear accumulation by enhancing its acetylation [20]. In osteoblasts, a 
number of HDACs and inhibitors have been shown regulate Runx2 expression along with other key 
osteoblast genes such as osteocalcin.  The mechanisms by which HDACi alter acetylation levels in 
osteoblasts affecting runx2 expression is not known.  
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Effects of HDACi in vitro on the crosstalk between bone cells has not yet been investigated. Given 
that select HDACi suppress NFATc1 expression and the ability of this transcription factor to 
suppress osteoblasts suggests that these compounds could also stimulate osteoblasts. It is likely 
however that it will be necessary to target the different HDACs that are important for individual cell 
differentiation and activity. Studies focussing on osteoclast-osteoblast-osteocyte communication in 
the presence of HDACi will be very valuable. In vivo studies using HDAC knock out models have 
revealed potential roles for HDACs in the interactions between the bone cells. For instance, in 
HDAC 5 global knock out mice there was an increase in sclerostin producing osteocytes with 
reductions in osteoblast number and defects in bone formation [74]. Other studies using global 
HDAC 5 knock out mice demonstrated increased bone resorption with higher numbers of 
osteoclasts covering the bone surface due to significantly high levels of RANKL produced by 
osteoblasts [86]. Similar observations of high bone resorption and RANKL levels were also evident 
in mice with HDAC4 knocked out in osteoblasts suggesting a role for HDAC4 in the 
communications between osteoblasts and osteoclasts [86].  It is important to note in studies using 
HDAC global knockout mice that all bone cells would be affected making it difficult to determine 
the exact mechanisms of the changes in bone parameters. To date, no studies have assessed effects 
of HDACi on the cross talk between bone cells. 
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6. HDACs and HDACi in bone diseases 
6.1 Periodontitis 
Periodontitis is a chronic inflammatory disorder affecting the tissues of the periodontium, 
including the gingiva, periodontal ligament, and alveolar bone. Characteristic features of this 
disease include soft tissue inflammation in response to gram-negative anaerobic bacteria that collect 
in the gingival pockets and associated alveolar bone loss [87]. In periodontitis gingival tissues, 
increased numbers of multinucleated TRAP positive osteoclasts have been detected along with high 
levels of RANKL and corresponding low levels of its inhibitor osteoprotegerin (OPG) [37]. 
Osteoblast numbers are also reported to be suppressed in periodontitis lesions harbouring 
Porphyromonas gingivalis (P.gingivalis), a common bacterium associated with periodontitis known 
to inhibit the differentiation and maturation of osteoblasts in vitro [88]. The alveolar bone loss 
characteristic of periodontitis leads to a loss of tooth support, and if untreated, can lead to tooth loss. 
The current treatment for periodontitis involves removal of the bacterial load through plaque 
removal, mechanical debridement and deep tissue scaling. Other treatments include the use of anti-
microbials and anti-inflammatories. Although a number of anti-resorptive agents have been 
investigated in disease models, to date none have progressed to the clinic (as reviewed in [89]).   
The potential of HDACi to treat periodontitis has been recently demonstrated using a novel 
HDACi, 1179.4b, shown to suppress alveolar bone loss in periodontitis [90].  Using a mouse model 
of P. gingivalis-induced periodontitis, oral administration of this broad acting HDACi 1179.4b (1 
mg/kg/day for 36 days) suppressed alveolar bone loss with an accompanying reduction in the 
number of TRAP positive cells in the gingiva and alveolar bone [90]. Interestingly, whilst inhibiting 
bone resorption, 1179.4b did not suppress gingival inflammation. It is important to note that the 
dosage used in this model was 100x lower compared to other broad acting HDACi such as 
vorinostat used in the treatment of malignancies. It is interesting that in the same periodontitis 
animal model, the HDAC-1 selective inhibitor MS-275 (Table 3) administered orally at 10 
mg/kg/day reduced levels of inflammation but had no effect on bone loss [90]. We have also 
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recently investigated the expression of HDACs 1-10 in gingival tissues collected from either 
patients with periodontitis and evidence of radiological bone loss, or patients with mild 
inflammation but no bone loss (non-periodontitis). At the mRNA level, HDACs 1 and 8 (class I) 
and HDAC 5 and 9 (class II) were all significantly up-regulated in periodontitis gingival tissues 
compared to the non-periodontitis group.  Similarly, these HDACs were strongly expressed at the 
protein level in both tissue groups based on immunohistochemistry. HDAC 1 was strongly 
expressed by the CD-3 and TNF-α positive inflammatory cells, whilst HDAC 5, 8 and 9 were 
strongly expressed by endothelial cells in the gingival tissues from patients with periodontitis [91]. 
However, further studies are needed to determine the best combination of inhibitors to use and 
whether other mechanisms of drug delivery may be possible including direct application to the 
gingiva.   
6.2 Rheumatoid Arthritis (RA) 
The chronic inflammatory disease, RA, is a very common destructive autoimmune disorder 
affecting about 1% of the world’s population [92]. RA is characterized by joint inflammation, 
synovial hyperplasia and associated destruction of bone and cartilage and progressive joint 
destruction. Excessive osteoclast-associated bone resorption is a characteristic feature in RA with 
studies demonstrating that osteoclast knock out mice are resistant to arthritis-induced bone loss [93, 
94]. Enhanced osteoclast formation has also been demonstrated in human RA synovial tissues [40, 
95-97]. In animal models of inflammatory arthritis and in human RA tissues, large multinucleated 
osteoclastic cells that resorb the subchondral bone, have been detected at sites of bone loss in 
synovial joints [40, 95-97]. Normal osteoblast function is impaired in arthritis, at sites of focal bone 
erosions, with reduced formation of mineralised bone at sites adjacent to synovial inflammation 
[60]. In these tissues, there was an abundance of cells expressing the early osteoblast marker Runx2, 
but these same cells did not express ALP and osteocalcin, suggesting that these cells were immature 
osteoblasts [60]. Current treatments for RA include non-steroidal anti-inflammatory drugs 
(NSAIDs), disease modifying anti-rheumatic drugs (DMARDS) and biologic DMARDS such as the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 19 
anti-TNF agents, infliximab and adalimumab. Although having beneficial effects on inflammation 
and disease activity, their abilities to suppress focal bone erosions were variable. Notably, it can 
take time for an effective treatment to be identified, during which structural joint damage can occur 
[98].  
The fact that HDACi are a new class of drugs that might help combat the ongoing bone 
damage associated with RA, has prompted a number of in vitro and in vivo RA related studies [7, 
21-23, 99-101]. The first study to assess effects of HDACi using an animal model of inflammatory 
arthritis was reported in 2003 [85]. It was found that topical treatment with the broad acting 
HDACi’s, phenyl butyrate (PB) (1% and 10% ointments) and TSA (1% ointment) suppressed joint 
swelling with significant reduction in synovial joint levels of TNF-α and no evidence of joint 
destruction in a rat adjuvant arthritis model (AIA) [99]. Subsequently, a number of other studies 
have demonstrated positive effects of broad acting HDACi to reduce RA disease activity. 
Vorinostat has been evaluated in rodent models of arthritis and anti-inflammatory activity was 
observed at doses of 50 mg/kg/day via subcutaneous injection [7] and 200 mg/kg/day via oral 
gavage [21]. However, these represent extremely high doses and raise concerns that long-term 
treatment of patients with chronic disease may reveal considerable unwanted off-target effects. A 
similarly broad acting HDACi, valproic acid (VPA), was also shown at 400mg/kg via i.p for 39 
days to reduce joint destruction in a collagen-induced arthritis model in mice, with both bone and 
cartilage damage significantly reduced [100]. A more recent study demonstrated that a novel 
HDACi, S-(ε)- 3-(1-(1-(benzo[d]oxazol-2-yl)-2-methylpropyl)-1H-1,2,3-triazol-4-yl)-N-
hydroxyacrylamide (referred to as NK-HDAC-1), which is more potent than vorinostat (10mg/kg 
and 30 mg/kg p.o every other day) suppressed bone erosion in collagen-induced arthritic mice 
[102]. The HDAC inhibitory profile of this inhibitor has not yet been reported. Another HDACi, 
MPT0G009 (3-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-5-yl]-N-hydroxyacrylamide), 
was recently shown at 25 mg/kg p.o. to decrease both cartilage and bone destruction in a murine 
model of adjuvant-induced arthritis and prevented reduction in bone mineral density and bone 
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mineral content. MPT0G009 is a non-selective HDACi that inhibits both class I (HDAC 1, 2, 3, 8) 
and class IIb (HDAC 6) HDACs (Table 1) [21]. Treatment with MPT0G009 at 25 mg/kg resulted in 
similar effects to that seen with vorinostat at 200 mg/kg. A more recent study showed that pan-
HDACi, including vorinostat, are quite toxic above 10 µM concentrations in cells and even at a 10 
mg/kg dose in rodents with collagen-induced arthritis, but were tolerated and optimally anti-
inflammatory at a lower in vivo dose of 1 mg/kg [25]. This suggests that the higher doses mentioned 
above should not be considered safe and efficacious, especially in already immune-compromised 
individuals suffering arthritis.  
In contrast to studies where broad acting HDACi have been used at high doses (50-100 
mg/kg), class- and isozyme-selective HDACi, such as NW-21 (targets HDAC 1 and 2) and MS-275 
(targets HDAC 1), BML-275 (targets HDAC 6) have been found to have anti-arthritic activity in 
rodent models at much lower doses (1-25 mg/kg/day) [7, 25]. For instance, in a collagen-induced 
arthritis (CIA) model, prophylactic treatment with MS-275 (3 and 10mg/kg/day s.c.) demonstrated 
significant anti-resorptive effects on the bone [7]. Therapeutic treatment with MS-275 (5 
mg/kg/day) also reduced joint narrowing and bone erosion in a rat adjuvant model of arthritis. In 
this study, treatment with vorinostat reduced bone loss, although its effects were not as marked as 
that observed with MS-275 [7]. Recent studies using a collagen antibody-induced arthritis (CAIA) 
model revealed that HDACi targeting HDAC 1 (NW-21 at 5 mg/kg/.day p.o and MS-275 at 10 
mg/kg/day p.o.) suppressed the formation of histologically and micro-CT-detectable bone erosions 
[103]. In contrast, the broad acting HDACi (1179.4b at 5 mg/kg/day p.o.) did not reduce bone 
erosions or disease activity in this model. The ability of selective-HDACi to inhibit HDAC activity 
at lower doses will accordingly result in fewer side effects when used for extended periods, as 
would be necessary in a chronic disease such as RA. Furthermore, lower doses of the HDACi, NW-
21 and MS-275, show significant benefits on bone remodeling. 
 Consistent with the positive effects of HDACi that inhibit HDAC 1, studies have shown that 
HDAC 1 is highly expressed in synovial tissues from patients with RA [28]. Importantly, this high 
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expression of HDAC 1 was correlated with expression of inflammatory cytokine TNF-α [29]. More 
recent studies have confirmed a role for HDAC 1 in the inflammatory tissue destruction in RA.  Use 
of siRNA against HDAC 1 in a CIA model was shown to suppress joint inflammation and 
destruction [57]. In this study, HDAC 1 mRNA expression levels were also confirmed to be high in 
RA synovial fibroblasts (RASFs). Interestingly, in these studies, the addition of TNF-α to the 
RASFs was shown to reduce HDAC 1 expression. These findings contrast those of others, which 
showed a correlation of HDAC 1 and TNF-α.  This difference could be related the use of an isolated 
cell population compared to total synovial tissues where HDAC 1 and TNF-α levels were shown to 
be correlated. 
The studies described above, highlight the potential of HDACi to reduce disease activity and 
focal bone erosions in RA. 
6.3 Myeloma Bone Disease 
Multiple myeloma (MM) is a haematological malignancy of immunoglobulin (Ig) producing 
plasma cells. Each year approximately 100,000 people are diagnosed with multiple myeloma 
worldwide. Osteolytic bone disease is a characteristic feature of more than 90% of patients with 
MM [104]. The imbalance between osteoblast bone formation and osteoclast bone resorption is 
responsible for the lytic disease observed [104]. The RANKL/RANK pathway has been shown to 
be important with high levels of RANKL and corresponding low levels of OPG correlating with 
disease activity [43, 105]. Current treatment for MM bone disease involves the use of 
bisphosphonates that are effective at inhibiting osteoclast activity. Bisphosphonates have however 
been shown to be associated with osteonecrosis of the jaw, but this is dependent upon a number of 
factors including route of administration, use with other agents and time of exposure to BPs [106]. 
A number of HDACi, including CR2408 (broad acting), JNJ-26481585 (broad acting) ACY-1215 
(targets HDAC 6) and panobinostat (broad acting), have shown promise for the treatment of MM 
with some inhibitors now in clinical trials, or used in the clinic [107-110]. However, to date, there 
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have been few studies investigating the effects of HDACi on MM bone disease. A novel broad 
acting hydroxamate HDACi, JNJ-26481585 (20 mg/kg/day via s.c. every other day), significantly 
reduced the formation of osteolytic lesions by more than 70% in a 5T2MM myeloma mouse model 
[111]. Reductions in both trabecular bone volume and number, along with reductions in the 
percentage of osteoclasts, were noted in mice treated with JNJ-26481585. Interestingly, the 
mineralizing surface and bone formation rate were increased in treated mice [111]. In subsequent 
studies, JNJ-26481585 (1.25 mg/kg via s.c. every other day) was tested in combination with 
bortezomib, a drug currently approved in the first line treatment for MM [109]. Effects on MM 
bone disease in the 5T2MM mouse model were assessed and the combination treatment was shown 
to cause a significant reduction in osteoclast numbers along with increased osteoblast numbers and 
increased trabecular bone volume [109].  
In the context of MM and MM bone disease, HDACi would appear to have both 
chemotherapeutic and anti-resorptive potential, as they may be able to suppress both MM plasma 
cell proliferation and osteoytic bone lesions. However, it is important to determine appropriate 
dosages required not only to target the cancer cells, but also to suppress osteoclasts without 
deleterious effects on healthy bone metabolism in the absence of cancer cells.  It may also be 
important to target the individual HDACs important in the different aspects of disease. 
 
7. Conclusions 
Numerous studies using both in vitro assays and animal models have shown that HDACi 
can have beneficial effects in the regulation of bone remodelling by suppressing osteoclast 
resorption and promoting osteoblast bone formation. In vitro, both broad acting and isozyme-
selective inhibitors have been shown to regulate osteoclasts by targeting a number of key 
intercellular signalling mechanisms particularly in the RANKL/RANK pathway. In osteoblasts, 
HDACi have been demonstrated to promote osteoblast proliferation and mineralisation. Various 
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HDACi have also been revealed to reduce bone loss by targeting osteoclast cells in animal models 
of periodontitis, RA and myeloma bone disease.  Translation of these pre-clinical findings to the 
clinic has however been limited most likely due to the complexity of physiological activities 
exhibited by different HDAC enzymes. It is likely that more isozyme-specific inhibitors, 
exemplified here to an extent by NW-21 and MS-275, will be needed to advance the development 
of HDACi as clinical therapies. Although their effects have only been observed in rodent models of 
bone loss to date, selective HDACi such as MS-275 and NW-21 have been found to suppress bone 
loss. The further development of these novel isozyme-selective HDACi is critical to gain an 
understanding of the roles that all HDACs play in physiological and pathological bone remodelling. 
Furthermore, this will be important in identifying which HDAC or HDACs should be targeted in a 
given disease. Another important finding is that many HDACi, both isozyme-selective and broad 
spectrum inhibitors, can be more beneficial in vivo at much lower doses than have often been 
investigated to date. It is important that compounds be reinvestigated in animal models such as 
those above at much lower, sub-toxic HDACi doses where they are likely to be better tolerated in 
chronic disease settings. More pharmacokinetic studies are also needed for many compounds to 
ensure that blood levels of HDACi do not exceed cytotoxic concentrations. As new selective 
inhibitors are developed and our understanding of their pharmacokinetics is improved, this area of 
epigenetic regulation is poised to reveal exciting new opportunities for therapeutic modulation of 
bone pathologies and other related inflammatory diseases. 
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Abbreviations 
HDAC – histone deacetylase 
HDACi – histone deacetylase inhibitors 
TSA - trichostatin A  
SAHA - suberanilohydroxamic acid  
CTCL - T-Cell lymphoma  
RA – rheumatoid arthritis 
RANKL - receptor activator of nuclear factor kappa B ligand  
TRAF-6 - tumour necrosis factor (TNF) receptor associated factor-6  
NFATc1 - nuclear factor of activated T cells  
siRNA - small interfering RNA  
shRNA - short hairpin RNA  
TRAP - tartrate resistant acid phosphatase  
BMM bone marrow macrophages 
PTH - parathyroid hormone  
BMPs - bone morphogenetic proteins 
ALP - alkaline phosphatase  
SOST - sclerostin  
MM – multiple myeloma 
RASFs - rheumatoid arthritis synovial fibroblasts  
TNF-α – tumour necrosis factor alpha 
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Table 1: Classes and locations of zinc-containing HDAC enzymes 
HDAC 
CLASS
a
 
HDAC CELLULAR LOCATION 
Class I HDAC 1 nucleus 
Class I HDAC 2 nucleus 
Class I HDAC 3 nucleus/cytoplasm  
Class I HDAC 8 nucleus/cytoplasm 
Class IIa HDAC 4 nucleus/cytoplasm 
Class IIa HDAC 5 nucleus/cytoplasm 
Class IIa HDAC 7 nucleus/cytoplasm 
Class IIa HDAC 9 nucleus/cytoplasm 
Class IIb HDAC 6 mainly cytoplasm 
Class IIb HDAC 10 mainly cytoplasm 
Class IV HDAC 11 nucleus 
a
 Class III involves 7 HDACs that do not use a catalytic zinc but rather NAD
+
 to effect lysine 
deacetylation. 
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Table 2: Effects of HDACi on osteoclasts and osteoblasts 
HDACi HDACs 
targeted 
HDAC IC50 Cell type Effect shown Dosage Reference 
1179.4b Class I and II 
 
HDAC 1 
 
HDAC 6 
 
 
 
48 nM 
 
107nM 
Osteoclasts – human peripheral 
blood mononuclear cells (PBMCs) 
Suppressed osteoclast formation 
and activity via suppression of 
TRAF-6 and NFATc1 
0.16-100 nM 
IC50<0.16 nM 
Cantley et al, 
2011 [19] 
vorinostat 
(SAHA)  
Class I and II 
 
HDAC 1  
HDAC 2  
HDAC 3  
HDAC 8  
 
HDAC 4  
HDAC 6  
HDAC 7  
HDAC 9 [112] 
 
 
68 nM 
164 nM 
48 nM 
1524 nM 
 
101 nM 
90 nM 
104 nM 
107 nM 
Primary bone marrow derived 
macrophages. Co-culture system 
with calvarial osteoblasts 
Suppressed osteoclast formation 
in co-culture system. Suppressed 
osteoclastogenesis in BMMs. 
300 nM Kim et al, 2009 
[13] 
trichostatin 
(TSA) 
Class I and II 
 
HDAC 1  
HDAC 2  
HDAC 3  
HDAC 8  
 
HDAC 4  
HDAC 6  
HDAC 7  
HDAC 9 [112] 
 
 
2 nM 
3 nM 
4 nM 
456 nM 
 
6 nM 
3 nM 
5 nM 
6 nM 
 
Primary bone marrow derived 
macrophages. Co-culture system 
with calvarial osteoblasts 
Suppressed osteoclast formation 
in co-culture system. Suppressed 
osteoclastogenesis in BMMs via 
suppression of c-fos. 
10 nM Kim et al, 2009 
[13] 
 
 
 
Mouse bone marrow cultures and 
RAW-D macrophage cell line 
 
Suppressed osteoclast 
differentiation (reduced number of 
TRAP positive (TRAP+) 
multinucleated cells)  
 
RAW-D cells – reduction in 
formation of TRAP+ 
5 nM, 10 nM, 20 
nM (BMMs) 
 
1 nM (RAW-D 
cells) 
 
Rahman et al, 
2003 [20] 
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multinucleated cells.  
 
Reduced nuclear translocation of 
NF-KB p65.  
 
C3H10T1/2 mouse mesenchymal 
cell line 
 
Induced osteopontin expression 50 ng/ml TSA 
 
Sakata et al, 2004  
[67] 
FR901228 
(Romidepsi
n) 
Class I HDAC 1 
and 2 inhibitor  
 
HDAC 1  
HDAC 2  
 
HDAC 4  
HDAC 6 [113]  
 
 
 
 
 
 
 
 
36 nM 
47 nM 
 
510 nM 
14,000 nM 
Rat bone marrow cells 
 
RAW-D cells 
Dose dependent suppression of 
the formation of TRAP+ 
multinucleated cells. 
 
RAW-D – inhibited TRAP cell 
formation – stimulated IFN-β 
gene expression 
0.2, 0.4, 0.6, 0.8, 
1.6 ng/ml 
Nakamura et al, 
2005 [15] 
sodium 
phenyl 
butyrate 
(NaB) 
Class I HDACs 
 
HDAC 1  
HDAC 2  
HDAC 3  
HDAC 8 
 
HDAC 4  
 
 
8.3 μM 
7 μM 
4.8 μM 
10.5 μM 
 
5725 μM 
Mouse bone marrow cultures and 
RAW-D macrophage cell line 
 
 
 
 
 
Suppressed osteoclast 
differentiation (reduced number of 
TRAP+ multinucleated cells).  
 
RAW-D cells – reduction in 
formation of TRAP+ 
multinucleated cells.  
 
0.5 mM 
 
 
 
 
0.1 mM (RAW-
D cells) 
Rahman et al, 
2003 [20] 
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HDAC 5  
HDAC 6  
HDAC 7  
HDAC 9 [114] 
6403 μM 
5881 μM 
4380 μM 
5614 μM 
MC3T3-E1 cells 
 
Mouse bone marrow macrophages 
 
Increased ALP production. 
 
 
Suppressed formation of TRAP+ 
multinucleated cells. 
 
0.5 mM and 1 
mM 
 
 
0.5 mM 
 
Iwami et al, 1993 
[66] 
 
MPT0G009 Class I and II 
HDACs 
 
HDAC 1  
HDAC 2 
HDAC 3  
HDAC 8  
 
HDAC 6 [21] 
 
 
 
4.6 nM 
5.2 nM 
1.9 nM 
22 nM 
 
8 nM 
RAW264.7 macrophages Suppressed TRAP cell formation 
via suppression of NF-kB and 
NFATc1. 
5 nM Hsieh et al, 2014 
[21] 
largazole Class I selective 
 
HDAC 1  
 
HDAC 6 [115] 
 
 
25 nM 
 
5700 nM 
C2C12 cells into osteoblasts Increased expression of ALP and 
Osteopontin. 
Increased Runx2 expression at 
mRNA level. 
Up to 50 nM Lee et al, 2011 
[69] 
MS-275 
(entinostat) 
HDAC 1 
Other HDACs 
[116] 
181 nM 
>1000 nM 
needed 
Osteoclasts – human PBMCs Suppressed osteoclast formation 
and activity. 
 
 
100 nM 
IC50=54 nM 
Cantley et al, 
2011 [19] 
Mouse bone marrow-derived 
macrophages (BMMs) 
 
Inhibited osteoclast formation in 
co-culture. 
Direct effect on osteoclast 
precursors – suppressed c-fos and 
NFATc1. 
Inhibited bone resorbing activity 
of mature osteoclasts. 
 
20 nM, 50 nM, 
100 nM 
 
Kim et al, 2012 
[44] 
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MC3T3-E1 cells and primary 
osteoblasts 
 
Stimulate cell proliferation and 
increased alkaline phosphatase 
(ALP) production.  
 
500 nM 
 
Schroeder, 2005 
[17] 
NW-21 HDAC 1  
HDAC 2  
Other HDACs 
[116] 
21 nM 
42 nM 
>300 nM 
Osteoclasts – human PBMCs Suppressed osteoclast formation 
and activity via suppression of 
NFATc1 and TRAF-6 
0.16 nM-100 
nM 
IC50 3.6 nM 
 
Cantley et al, 
2015 [103] 
2664.12 HDAC 6  
Other HDACs 
[55] [116] 
29 nM 
> 100 nM 
Osteoclasts – human PBMCs Suppress osteoclast activity. 20 nM and 100 
nM 
IC50>100 nM 
Cantley et al, 
2011 [19] 
 
Table 3: Effects of HDACi in animal models with pathogenic bone loss.  
Drug/Compound 
name 
HDACs targeted HDAC IC50 Disease 
type 
Bone Effects Dosages 
Tested 
Reference 
1179.4b Class I and II  
 
HDAC 1  
 
HDAC 6  
 
 
48 nM 
 
107 nM 
Periodontiti
s – oral 
inoculation 
model in 
balb/c mice 
Suppressed alveolar 
bone loss (assessed 
via micro computed 
tomography (CT) and 
histology). Reduced 
numbers of TRAP+ 
cells. 
1mg/kg/day 
p.o. for 36 
days (oral 
gavage) 
Cantley et 
al, 2011 
[90] 
JNJ-26481585 Class I and II 
 
HDAC 1  
HDAC 2 
 
HDAC 10  
HDAC 11 [117] 
 
 
0.11 nM 
0.33 nM 
 
0.46 nM 
0.37 nM 
 
5T2MM 
myeloma 
mouse 
model – 
therapeutic 
effects. 
Reduced formation of 
osteolytic lesions by 
more than 70%. 
Reductions in both 
trabecular bone 
volume and number 
along with the 
percentage of 
osteoclasts. 
5T2MM – 
treatment 
following 
serum 
paraprotein 
detection. 20 
mg/kg, every 
other day, s.c. 
for 3.5 
Deleu et a, 
2009 [111] 
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Mineralizing surface 
and bone formation 
rate both increased. 
weeks. 
 
MPT0G009 Class I and II  
 
HDAC 1  
HDAC 2  
HDAC 3  
HDAC 8  
 
HDAC 6 [21] 
 
 
4.6 nM 
5.2 nM 
1.9 nM 
22 nM 
 
8 nM 
Adjuvant 
induced 
arthritis 
(AIA) 
Ameliorated bone 
destruction and 
prevented decrease in 
bone mineral density 
and bone mineral 
content. 
 
25 mg/kg p.o.  Hseih et al, 
2014 [21] 
sodium phenyl 
butyrate (PB) 
Class I HDACs 
 
HDAC 1  
HDAC 2  
HDAC 3  
HDAC 8 
 
HDAC 4  
HDAC 5  
HDAC 6 
HDAC 7  
HDAC 9 [114] 
 
 
8.3 μM 
7 μM 
4.8 μM 
10.5 μM 
 
5725 μM 
6403 μM 
5881 μM 
4380 μM 
5614 μM 
AIA Treated groups – no 
pannus formation or 
joint destruction  
Topical 
application 
1% and 10% 
PB ointment 
Chung et 
al, 2003 
[99] 
trichostatin A 
(TSA) 
Class I and II  
 
HDAC 1  
HDAC 2  
HDAC 3  
HDAC 8  
 
 
HDAC 4  
HDAC 6  
HDAC 7  
 
 
2 nM 
3 nM 
4 nM 
456 nM 
 
6 nM 
3 nM 
5 nM 
6 nM 
AIA Treated groups – no 
pannus formation or 
joint destruction 
Topical 
application 
1% TSA 
ointment 
Chung et 
al, 2003 
[99] 
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HDAC 9 [112] 
vorinostat 
(SAHA) 
Class I and II 
 
HDAC 1  
HDAC 2  
HDAC 3  
HDAC 8  
 
HDAC 4  
HDAC 6  
HDAC 7  
HDAC 9 [112]  
 
 
68 nM 
164 nM 
48 nM 
1524 nM 
 
101 nM 
90 nM 
104 nM 
107 nM 
Mouse 
collagen 
induced 
arthritis 
(CIA) – 
prophylactic 
treatment. 
 
Rat CIA - 
prophylactic 
treatment 
and 
therapeutic 
treatment. 
Mouse - Assessed via 
radiological score on x 
rays, micro CT of 
tibae (systemic bone 
loss) and histology. At 
both doses (high and 
low) demonstrated 
some bone protective 
effects. 
 
Rat CIA – high dose 
Vorinostat attenuated 
bone erosion 
High – 
50mg/kg/day 
s.c. 
Low – 
5mg/kg/day 
s.c. 
After 40 days 
 
Rat CIA  
High dose 
50mg/kg/day 
p.o. 
 
Lin et al, 
2007 [7] 
C57BL/KaL
wRij mice 
No bone loss observed 
in naïve mice increase 
in number of 
osteogenic colonies, 
increased serum 
osteocalcin, increased 
osteoblast numbers in 
endocortical and 
trabecular bone 
surfaces  
100mg/kg i.p. 
3 times per 
week for 3 
weeks 
Xu et al, 
2013 [78] 
Adjuvant 
induced 
arthritis 
(AIA) 
Ameliorated bone 
destruction and 
prevented decrease in 
bone mineral density 
and bone mineral 
content. 
 
200 mg/kg 
p.o. daily 
from day 2 to 
21. 
Hseih et al, 
2014 [21] 
Rat CIA Reduced osteoclast 1mg/kg s.c Lohman et 
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like cells in the joint 
(ED1+ cell) at 
1mg/kg/day, but 
increased numbers 
with 5mg/kg/day. 
daily 
5mg/kg s.c 
daily 
 
al, 2016 
[25] 
valproic acid 
(VPA) 
Class I and II 
 
HDAC 1  
HDAC 2  
HDAC 3 
HDAC 8  
 
HDAC 6, 7, 9 
[112]   
 
 
 
1.58 mM 
3.068 mM 
3.071 mM 
7.442 mM 
 
 > 10,000 mM 
Mouse CIA Histology revealed 
well-preserved 
proximal 
interphalangeal joints 
with negligible 
cartilage and bone 
destruction.  
400mg/kg via 
i.p. starting 
on day 21 
until day 60. 
Saouaf et 
al, 2009 
[100] 
ITF-2357/ 
givinostat 
Class I and II  
 
HDAC 1  
HDAC 2  
HDAC 3  
 
HDAC 4  
HDAC 6  
HDAC 7 [112] 
 
 
28 nM 
56 nM 
21 nM 
 
52 nM 
27 nM 
163 nM 
Rat AIA 
 
Mouse CIA 
Prophylactic and 
Therapeutic – 
suppressed joint 
destruction in both 
AA and CIA 
10mg/kg p.o. 
 
Joosten et 
al, 2011 
[22] 
FR901228 
(romidepsin) 
Class I HDAC 1 
and 2 inhibitor  
 
HDAC 1  
HDAC 2  
 
HDAC 4  
HDAC 6 [113]  
 
 
 
 
36 nM 
47 nM 
 
510 nM 
14000 nM 
AIA Prophylactic treatment 
– suppressed disease 
development, no bone 
destruction. 
 
Therapeutic treatment 
– bone destruction less 
severe and number of 
TRAP+ cells was 
significantly 
Prophylactic 
- 0.5 mg/kg 
 
 
 
 
 
Therapeutic – 
1 mg/kg. 
 
Nakamura 
et al, 2005 
[15] 
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decreased  
intradermally 
injected into 
tail 
 
largazole Class I selective  
 
HDAC 1  
 
HDAC 6 [115]  
 
 
25 nM 
 
5700 nM 
A mouse 
calvarial 
bone 
formation 
assay and 
the rabbit 
calvarial 
bone 
fracture 
healing 
model 
Mouse calvarial assay 
- induced woven bone 
formation, more 
significant at lower 
concentration than 
higher concentration.  
Rabbit calvarial 
fracture assay - 
macroporous biphasic 
calcium phosphate 
scaffold with 
largozole – newly 
formed bone with 
combination. 
Mouse - 
Lower 10 µM 
vs. 50 µM. 
Collagen 
sponges with 
largazole 10 
μM or 50 
μM) 
Rabbit – 
100nM or 
250nM. 
Added to the 
bone graft 
substitute (10 
mg). 
Lee et al, 
2011 [69] 
MS-275 
(entinostat) 
HDAC 1 selective 
 
HDAC 1 (181 nM) 
Other HDACs  
[116] 
 
 
181 nM 
>1000 nM 
 
Periodontiti
s – oral 
inoculation 
model in 
mice. 
 
No effect on alveolar 
bone loss as assessed 
via micro CT and 
histology.  
10 mg/kg/day 
p.o. for 36 
days (oral 
gavage) 
Cantley et 
al, 2011 
[90] 
IL-1-
induced 
mouse 
calvarial 
bone loss 
Attenuated IL-1 
induced bone 
destruction of 
calvaria. 
2 mg/kg/day 
i.p for 8 days 
Kim et al, 
2012 [44] 
Mouse 
collagen 
induced 
Mouse CIA - 
Assessed via 
radiological score on x 
High dose – 
10 mg/kg/day 
s.c.  
Lin et al, 
2007 [7] 
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arthritis 
(CIA) - 
prophylactic 
treatment. 
 
Rat CIA - 
prophylactic 
treatment 
and 
therapeutic 
treatment. 
 
rays, micro CT of 
tibae (systemic bone 
loss) and histology. 
Low doses – 
demonstrated strong 
anti-erosion effects. 
No bone erosion in 
high dose. 
Protection against 
systemic bone loss. 
Rats – 3 mg/kg – MS-
275 prevented bone 
erosion. At 1 mg/kg – 
strongly suppressed 
bone erosion. 
Rat CIA therapeutic – 
at 5 mg/kg only slight 
reduction in bone 
erosion and joint 
narrowing evident. 
Low dose – 3 
mg/kg/day 
s.c. 
After 40 days 
 
Rat CIA 
0.3, 1, 3 
mg/kg/day 
s.c. 
NW-21 Class I Selective 
for HDAC 1 and 2 
 
HDAC 1  
HDAC 2  
Other HDACs 
[116] 
 
 
 
21 nM 
42 nM 
>300 nM 
Collagen 
antibody 
induced 
arthritis 
(CAIA) 
mouse 
model 
Suppressed bone 
destruction in 
radiocarpal joints 
(assessed via micro 
CT and histology). 
Significant reduction 
in numbers of TRAP+ 
cells on bone surface 
5mg/kg/day 
p.o. for 10 
days (oral 
gavage) 
 
Cantley et 
al, 2015 
[103] 
BML-281 Selective HDAC 6 
inhibitor  
 
HDAC 1  
HDAC 2  
HDAC 3  
 
 
 
271 nM 
252 nM 
0.42 nM 
Rat CIA Reduced osteoclast 
like cells in the joint 
(ED1+ cell) at 
1mg/kg/day, but 
increased numbers 
with 5mg/kg/day. 
1mg/kg s.c 
daily 
5mg/kg s.c 
daily 
 
Lohman et 
al, 2016 
[25] 
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HDAC 8  
 
HDAC 6 
HDAC 10  
6851 nM 
 
0.002 nM 
90.7 nM 
NK-HDAC-1 
 
S-(ε)- 3-(1-(1-
(benzo[d]oxazol-
2-yl)-2-
methylpropyl)-
1H- 1,2,3-triazol-
4-yl)-N-
hydroxyacrylamid
e 
Unknown  Mouse CIA 
– 
therapeutic 
effects 
Inhibited pannus 
formation. 
Suppression of joint 
erosion assessed via 
histology.  
Treatment 
from day 26. 
10 mg/kg and 
30 mg/kg p.o. 
every other 
day for 24 
days. 
Li et al, 
2013 [102] 
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Highlights 
 
 HDACi can regulate bone remodelling by suppressing osteoclasts and promoting osteoblasts via 
targeting key intercellular signalling molecules and transcription factors. 
 
 HDAC isozymes can have differing roles in the differentiation and function of bone cells - 
osteoclasts, osteoblasts and osteocytes.  
 
 Novel isozyme-specific HDACi are critical to elucidate HDAC roles in bone remodelling and the 
communication between bone cells. 
 
 For non-malignancies, such as periodontitis and inflammatory arthritis, HDACi can be more 
beneficial in vivo at much lower doses. 
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